Research institution
Royal Marsden NHS Foundation Trust Clinical Trials
Studies where Royal Marsden NHS Foundation Trust is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 42Colorectal Cancer, Gastro-oesophageal Adenocarcinoma
Cohort Study to eLucidAte Causes, Behaviour and Outcomes of gastRo Intestinal Tract Cancers in the Young
This study aims to better understand how gastrointestinal (digestive system) cancers develop and how they respond to treatment in young adults, in order to improve ways to prevent, diagnose, and manage these cancers in this age…
- Conditions
- Colorectal Cancer, Gastro-oesophageal Adenocarcinoma, Hepato-Biliary Carcinoma in Situ Nos
- Trial name
- CLARITY (NCT07903571)
- Testing
- Research blood samples
- Volunteers
- 200 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer
Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
The SAFE-DE study investigates whether circulating tumour DNA (ctDNA) testing can guide adjuvant treatment decisions in patients with stage I breast cancer, identifying those who may be able to avoid chemotherapy after surgery.
- Trial name
- Safe-De (NCT05058183)
- Testing
- ctDNA
- Where
- 13 sites in United Kingdom
- Volunteers
- 800 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Endometrial Carcinoma (EC)
A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility
The goal of this clinical trial is to assess the safety and feasibility of using a new form of radiotherapy technology, known as CT online-adaptive radiotherapy, to reduce the number of treatment sessions required in…
- Trial name
- SHORTEN (NCT07675733)
- Testing
- Hypofractionated CT online adaptive radiotherapy (CT-OART) with dose of 30 Gray in 5 fractions, over one and a half weeks
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Prostate Cancer in UK Prisons: A Retrospective Data Analysis
Prostate cancer is the most common cancer affecting men in the United Kingdom (UK) and is the most common cancer in UK prisons. Early diagnosis is vital because treatment is more effective when the disease is detected at an early…
- Trial name
- PRISON-UK (NCT07870707)
- Where
- United Kingdom
- Volunteers
- 9,007 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Patient and Provider Perspectives on Genetic Risk Profiling
A qualitative interview study exploring the patient and provider perspectives on the clinical utility of genetic risk profiling in routine clinical practice.
- Trial name
- PPP (NCT07741929)
- Testing
- Qualitative interview
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Pancreatic Cancer
A Phase-II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer
Pain from advanced pancreatic cancer is often difficult to control. This pain commonly occurs when the cancer affects a network of nerves in the abdomen called the coeliac plexus.
- Trial name
- PANCPLEX (NCT07689955)
- Testing
- IMRT
- Volunteers
- 52 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST)
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer.
- Conditions
- Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST), Colorectal Cancer, Biliary Tract Cancer
- Trial name
- CURTAIN (NCT07673861)
- Testing
- Marsden360 ctDNA test and GTAB review
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer, Triple Negative Breast Cancer
Breast Cancer Evolution During Neoadjuvant Systemic Therapy
BELIEVE is a translational research study that aims to collect samples of breast cancer tissue and blood from individuals undergoing breast cancer treatment (such as chemotherapy, targeted therapy and immunotherapy) before…
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, ER+ Breast Cancer, HER2+ Breast Cancer
- Trial name
- BELIEVE (NCT06681064)
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions
DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT).
- Trial name
- DESTINATION 2 (NCT06638541)
- Testing
- Prostate radical radiotherapy
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 54 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer, Metastatic Breast Cancer
Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution
FORTITUDE is a translational research study that aims to collect serial multi-site needle biopsy samples of tumour tissue and blood from metastatic breast cancer patients.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer
- Trial name
- FORTITUDE (NCT07084571)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Completed, with results posted
All 10Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage I
SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects
This is a single arm, multi-centre, phase II open label study of nivolumab with stereotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer.
- Trial name
- STILE (NCT03383302)
- Testing
- Stereotactic body radiotherapy, Nivolumab
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer, Metastasis
Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
This multi-center, phase II trial will be conducted in men with castration resistant prostate cancer. The aim of the TRAP trial is to test whether a new precise radiotherapy technique called stereotactic body radiotherapy (SBRT)…
- Conditions
- Prostate Cancer, Metastasis, Toxicity Due to Radiotherapy, Circulating Tumour DNA
- Trial name
- TRAP (NCT03644303)
- Testing
- SBRT + ADT
- Where
- 7 sites in United Kingdom
- Volunteers
- 86 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Melanoma, Cancer
Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833
The study is a first in man, dose escalation study to evaluate the safety, tolerability and how the drug works in the body in patients with all solid tumours.
- Trial name
- PanRAF (NCT02437227)
- Testing
- CCT3833
- Where
- 2 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Thoracic Tumours
Pembrolizumab and Palliative Radiotherapy in Lung
Lung cancer is the second most common cancer in the UK with around 43,500 new patients diagnosed each year. About 69% of patients are diagnosed with advanced stage disease and at present these patients would be expected to…
- Trial name
- PEAR (NCT02587455)
- Testing
- Pembrolizumab, Radiotherapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Soft-tissue Sarcoma
Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma
The objective of this trial is to assess the safety and tolerability of combining compound 451238 and radiotherapy, treating advanced STS.
- Trial name
- NCT03602833
- Testing
- Compound 451238
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Royal Marsden NHS Foundation Trust